Skip to content
DMACDiaMedica Therapeutics Inc.

Earnings

When DiaMedica Therapeutics Inc. reports, what it reported each quarter, and how the stock took the results.

35 quarters. Mar 31, 2018 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 29, after the close

Mon, Mar 29, 2027in 131 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 11 – 31

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Net income
-$8.74M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2021 n/m, Q2 2021 n/m, Q1 2021 n/m, Q3 2020 n/m

Quarter by quarter

Q4 2023—

Latest results

  1. Q3 2026Nov 12, 2026, after the closeThe release
    Revenue
    —
    —
    Net income
    -$11.31M
    N/M
    EPS
    —
    —
    Enrollment in the pivotal Phase 2/3 ReMEDy2 trial (NCT05065216) has reached the prespecified threshold of 200 participants for the trial's planned interim analysis.
  2. Q2 2026Aug 10, 2026, after the closeThe release+3.3%by the close of Aug 11
    Revenue
    —
    —
    Net income
    -$10.14M
    N/M
    EPS
    —
    —
  3. Q1 2026May 6, 2026, after the closeThe release0.3%by the close of May 7
    Revenue
    —
    —
    Net income
    -$10.04M
    N/M
    EPS
    —
    —
  4. Q4 2025Mar 30, 2026, after the closeThe release+1.7%by the close of Mar 31
    Revenue
    —
    —
    Net income
    -$8.74M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 12, 2026 · after-hoursNov 12, 202643 d10-Q————
Q2 2026Jun 30, 2026Aug 10, 2026 · after-hoursAug 10, 202641 d10-Q———+3.3%
Q1 2026Mar 31, 2026May 6, 2026 · after-hoursMay 6, 202636 d10-Q———0.3%
FY 2025
Q4 2025derivedDec 31, 2025Mar 30, 2026 · after-hoursMar 30, 202689 d10-K———+1.7%
Q3 2025Sep 30, 2025Nov 12, 2025 · after-hoursNov 12, 202543 d10-Q———13.9%
Q2 2025Jun 30, 2025Aug 12, 2025 · after-hoursAug 12, 202543 d10-Q———+15.4%
Q1 2025Mar 31, 2025May 13, 2025 · after-hoursMay 13, 202543 d10-Q———+2.4%
FY 2024
Q4 2024derivedDec 31, 2024Mar 17, 2025 · after-hoursMar 17, 202576 d10-K———13.0%
Q3 2024Sep 30, 2024Nov 13, 2024 · after-hoursNov 13, 202444 d10-Q———3.3%
Q2 2024Jun 30, 2024Aug 7, 2024 · after-hoursAug 7, 202438 d10-Q————
Q1 2024Mar 31, 2024May 8, 2024 · after-hoursMay 8, 202438 d10-Q————
Earlier years, FY 2018 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 12, 2026036602
10-QAug 10, 2026026792
10-QMay 6, 2026015220
10-KMar 30, 2026010342
10-QNov 12, 2025034469
10-QAug 12, 2025026207
10-QMay 13, 2025016488
10-KMar 17, 2025008018
10-QNov 13, 2024034925
10-QAug 7, 2024025198

Provenance

ProvenanceData status and checks

DiaMedica Therapeutics Inc. · CIK 1401040 · Engraved from SEC EDGAR